financetom
Business
financetom
/
Business
/
Evercore to acquire British boutique investment bank Robey Warshaw for $196 million
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Evercore to acquire British boutique investment bank Robey Warshaw for $196 million
Aug 21, 2025 5:36 AM

July 30 (Reuters) - Evercore ( EVR ) will acquire

British boutique investment bank Robey Warshaw for $196 million,

the U.S. investment bank said on Wednesday.

Payment will be made in two tranches, half in Evercore ( EVR )

shares when the deal closes and the remainder a year later in

either cash or stock, Evercore's ( EVR ) statement said.

The transaction for Mayfair-based Warshaw, whose partners

include former UK finance minister George Osborne, is expected

to close in the fourth quarter of 2025.

New York-based Evercore ( EVR ) said it expects the deal to be

earnings accretive in the first full year after the acquisition

and beyond.

Robey Warshaw was founded in 2013 by former Morgan Stanley

bankers Simon Robey and Philip Apostolides, along with UBS

banker Simon Warshaw, and has built a reputation as a leading

boardroom adviser to Britain's largest corporates over the past

decade.

"Robey Warshaw brings extraordinary, long-standing

relationships with some of the world's leading multinational

companies," Evercore ( EVR ) Chairman and Chief Executive John Weinberg

said in a statement.

The deal will enhance Evercore's ( EVR ) market position in the

largest M&A advisory market in Europe, the company's statement

said, adding that it will open further significant client

opportunities across the EMEA region and globally.

Simon Robey, co-founder of Robey Warshaw, said: "Our clients

will continue to get the personal attention and care we have

always strived to provide. They will also be able to benefit

from greater global reach, broad product capabilities and sector

expertise. Evercore ( EVR ) is the right home for all of us."

The latest consolidation in the sector follows Mizuho

Financial Group's $550 million deal for boutique investment bank

Greenhill in 2023 and Mediobanca's purchase of London-based Arma

Partners in the same year, the price of which was undisclosed.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Johnson & Johnson to invest $2 billion to boost US manufacturing as drug tariffs loom
Johnson & Johnson to invest $2 billion to boost US manufacturing as drug tariffs loom
Aug 21, 2025
(Reuters) -Johnson & Johnson ( JNJ ) committed to invest $2 billion in North Carolina on Thursday to expand the drugmaker's U.S. manufacturing presence as potential drug import duties from President Donald Trump's administration loom. J&J said it plans to build a new facility at Tokyo-based Fujifilm Diosynth's manufacturing site in Holly Springs, North Carolina, over the next 10 years....
Chinese cosmetics firm Yatsen Q2 revenue rises
Chinese cosmetics firm Yatsen Q2 revenue rises
Aug 21, 2025
Overview * Yatsen Q2 2025 rev rises 36.8% yr/yr to RMB1.09 bln * Net loss narrows 77.2% to RMB19.5 mln, non-GAAP net income positive * Gross margin improves to 78.3%, driven by higher-margin product sales Outlook * Yatsen expects Q3 2025 net revenues between RMB778.6 mln and RMB880.1 mln * Company forecasts Q3 2025 revenue growth of 15% to 30%...
Yatsen Reports Q2 Adjusted Earnings, Higher Revenue; Q3 Sales Outlook Set
Yatsen Reports Q2 Adjusted Earnings, Higher Revenue; Q3 Sales Outlook Set
Aug 21, 2025
05:25 AM EDT, 08/21/2025 (MT Newswires) -- Yatsen Holding ( YSG ) reported Q2 non-GAAP earnings Thursday of 0.13 Chinese renminbi ($0.02) per diluted American depositary share, swinging from a loss of 0.67 renminbi a year earlier. Analyst estimates were not readily available for comparison. Net revenue for the quarter ended June 30 was 1.09 billion renminbi, compared with 794.5...
Alvotech Says European Commission Approved Mynzepli to Treat Retinal Diseases
Alvotech Says European Commission Approved Mynzepli to Treat Retinal Diseases
Aug 21, 2025
05:29 AM EDT, 08/21/2025 (MT Newswires) -- Alvotech ( ALVO ) and UK-based Advanz Pharma said Thursday that their Mynzepli fusion protein was approved by the European Commission to treat retinal diseases, including neovascular age-related macular degeneration. The companies said the approval was based on non-clinical and clinical similarity data, which included a confirmatory efficacy study comparing Mynzepli with Bayer's...
Copyright 2023-2025 - www.financetom.com All Rights Reserved